Amiselimod - A new treatment for Ulcerative Colitis

Ulcerative Colitis

The purpose of this study is to learn about the safety and effectiveness of an investigational drug called amiselimod in the treatment of ulcerative colitis. In addition, the study will investigate how the body absorbs, distributes, and removes the study drug.

Trial Status
Trial Phase
Phase 2 Drug Trial
Trial contact details
Contact Person
IBD Clinical Trials Unit
What you need to know

What is involved for you?

  • People aged 18 – 75
  • Confirmed diagnosis of mild to moderate Ulcerative Colitis at least 12 weeks prior to joining the study
  • Willingness to complete a daily diary
  • Dosage of any current medications for ulcerative colitis is stable


  • Other disease that may impact study (eg Crohn’s disease)
  • Previous surgery for ulcerative collitis
  • Current or recent infection
  • Current immunodeficiency
  • History of cardiac conditions
  • Certain medications may make you ineligible to participate

Trial dates

July 2022 to October 2023

All research clinical trials news

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.



Mater launches trial of Australian-first flu vaccine

Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...



Stephanie Guilas is improving outcomes for mums and bubs through research

Working as a research assistant in an immunology research lab, Yvonne Gautam learnt what a clinical trial was after being asked to set up a lab for a Phase Two clinical trial.



Clinical Trials Coordinator Yvonne Gautam is working towards creating better treatments for patients with diabetes

Displaying results 1-3 (of 16)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|